Registered title, quoted from ClinicalTrials.gov
Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07945353, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically confirmed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
Inclusion criterion 2
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Inclusion criterion 5
Hematologic function: absolute neutrophil count ≥1.0 × 10\^9/L, platelet count ≥50 × 10\^9/L, and hemoglobin ≥80 g/L.
Inclusion criterion 8
Hepatic function: total bilirubin ≤1.5 × the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3 × ULN, and serum albumin ≥30 g/L.
Inclusion criterion 9
Renal function: serum creatinine <1.5 × ULN and creatinine clearance ≥50 mL/min, calculated using the standard Cockcroft-Gault formula. For renal impairment caused by tumor compression, creatinine clearance ≥30 mL/min is acceptable.
Inclusion criterion 10
Coagulation function: unless the participant is receiving anticoagulant therapy and the coagulation parameters (PT/INR and APTT) are within the expected range for the anticoagulant treatment, international normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (APTT) ≤1.5 × ULN.
Inclusion criterion 11
Active infection with human immunodeficiency virus (HIV) or syphilis.
Exclusion criterion 14
Pregnant or breastfeeding women.
Exclusion criterion 15
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07945353, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
- MALT lymphoma involving, but not limited to, the following sites: orbit, parotid gland, thyroid, Helicobacter pylori (H. pylori)-negative gastric MALT lymphoma, lung, intestine, prostate, and other sites.
For gastric MALT lymphoma, H. pylori negativity must be confirmed by a 13C-urea breath test or gastric mucosal histology. For patients with unknown prior H. pylori status who have previously received H. pylori eradication therapy, serum H. pylori antibody may remain positive. In such cases, at least 1 year must have elapsed since completion of eradication therapy, and repeat gastroscopy and/or breath testing must be negative. Patients with a history of H. pylori infection must have the eradication regimen documented. If t(11;18) testing is available, the result should also be documented for exploratory analysis.
- Lugano stage I-II disease. Staging will be performed according to the Lugano classification. Limited-stage disease eligible for this study is defined as all known MALT lymphoma lesions being confined to a single organ or paired organs, with or without regional lymph node involvement, and all disease being safely amenable to coverage by limited-field curative-intent involved-site radiotherapy (ISRT).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Ability to understand and willingness to voluntarily provide written informed consent.
- Adequate organ function, defined as follows:
- Hematologic function: absolute neutrophil count ≥1.0 × 10\^9/L, platelet count ≥50 × 10\^9/L, and hemoglobin ≥80 g/L.
- Hepatic function: total bilirubin ≤1.5 × the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3 × ULN, and serum albumin ≥30 g/L.
- Renal function: serum creatinine <1.5 × ULN and creatinine clearance ≥50 mL/min, calculated using the standard Cockcroft-Gault formula. For renal impairment caused by tumor compression, creatinine clearance ≥30 mL/min is acceptable.
- Coagulation function: unless the participant is receiving anticoagulant therapy and the coagulation parameters (PT/INR and APTT) are within the expected range for the anticoagulant treatment, international normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (APTT) ≤1.5 × ULN.
Exclusion Criteria:
- Major surgery within 4 weeks before enrollment, except for diagnostic surgery.
- Uncontrolled concomitant diseases, including cardiovascular or cerebrovascular disease, coagulation disorders, and severe infectious diseases, including but not limited to:
- severe acute or chronic infections requiring systemic treatment;
- symptomatic congestive heart failure (New York Heart Association class III-IV);
- symptomatic or inadequately controlled arrhythmia;
- inadequately controlled arterial hypertension despite standard treatment (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
- unstable angina;
- active peptic ulcer disease or bleeding disorders.
- Severe concomitant diseases that may interfere with routine treatment.
- Known active interstitial pneumonia.
- Viral hepatitis and other active infections:
- Active chronic hepatitis B infection, defined as positive hepatitis B virus (HBV) DNA. Patients with latent or prior HBV infection (defined as positive hepatitis B surface antigen [HBsAg] or total hepatitis B core antibody [HBcAb]) may be enrolled if HBV DNA is undetectable at screening. Such patients must be willing to undergo regular HBV DNA monitoring and receive appropriate antiviral therapy as required by the study.
- Patients with positive hepatitis C virus (HCV) antibody may participate only if HCV RNA is negative by polymerase chain reaction (PCR).
- Active infection with human immunodeficiency virus (HIV) or syphilis.
- Pregnant or breastfeeding women.
- Dysphagia or inability to take oral medication on a long-term basis.
- Patients considered unsuitable for participation in the study by the investigator.
Quoted from ClinicalTrials.gov, NCT07945353, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07945353, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.